

SUPPORTING SINGAPORE'S RIE2030 AMBITION

ALL Industry-Sponsored Trials (ISTs)

submitted to DSRB since 1 April 2026 onboard automatically to the **DSRB Industry Green Lane** review pathway.

SUPPORTING NATIONAL TARGETS

≤40 WORKING DAYS

For submissions that are:

- ✓ Regulatory-compliant
- ✓ Consistent
- ✓ Complete



MEASURABLE PROGRESS

40% in average IST turnaround time
Improvement

Following implementation of DSRB Industry Green Lane review pathway

KEY ENABLERS



Active Monitoring

IST submissions are continuously monitored for prompt review



Process Enhancements

Review workflows are regularly refined to improve efficiency.



Quality Assurance

Maintained through audits on DSRB reviews.



DSRB Industry Green Lane review FAQs



Q1. What is the objective of the DSRB Industry Green Lane review pathway?

The DSRB Industry Green Lane review pathway supports Singapore's RIE 2030 ambition to accelerate clinical trial start-up timelines by actively monitoring review progress and implementing process improvements to facilitate timely ethics review outcomes for industry-sponsored trials (ISTs).

Q2. What studies qualify for the DSRB Industry Green Lane review pathway?

All new studies sponsored by industry partners (e.g. pharmaceutical companies, MNCs, etc), also known as industry-sponsored trials (ISTs) qualify for the DSRB Industry Green Lane review.

Q3. Does the target review timeline under RIE 2030 apply to all ISTs?

Yes. All ISTs submitted to DSRB will be reviewed under the DSRB Industry Green Lane review pathway, which commits to the review timeline of ≤ 40 working days set under RIE 2030 targets.

Sponsors can facilitate timely review by ensuring that submissions are complete, consistent and compliant with applicable regulatory and ethical requirements. Where clarifications, revisions or additional information are required, review timelines may be affected.

Q4. What are the charges for the DSRB Industry Green Lane review pathway?

The standard IRB Review Fees for studies initiated by industry or commercial entities will apply. Please refer to DSRB FAQs at <https://ethics.gri.nhg.com.sg/dsrb-faqs/>

Q5. Will DSRB Industry Green Lane reviews receive less scrutiny?

No. The DSRB Industry Green Lane review pathway is designed to improve review efficiency through enhanced monitoring, prioritisation and streamlined processes. It does not reduce the rigor of ethical review or change the criteria used to assess a study.

DSRB operates within NHG Health AAHRPP-accredited Human Research Protection Programme and remains committed to maintaining internationally recognised standards for the protection of research participants and the ethical conduct of research.

Q6. How can sponsors learn more about the DSRB Industry Green Lane review pathway?

Sponsors interested to understand more may contact us for a discussion:

- Yuan Ting - yuan.ting.leong@nhghealth.com.sg
- Amber - amber.lim.sg@nhghealth.com.sg